Puma Biotechnology, Inc.
PBYI
$5.06
$0.193.90%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -32.36% | 11.37% | 5.12% | -18.15% | 43.53% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -32.36% | 11.37% | 5.12% | -18.15% | 43.53% |
| Cost of Revenue | -58.16% | 15.42% | -1.60% | -42.77% | 119.04% |
| Gross Profit | -17.77% | 10.19% | 7.30% | -5.64% | 20.11% |
| SG&A Expenses | -0.01% | -27.73% | -19.06% | -15.02% | -26.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.20% | -7.03% | -8.77% | -19.46% | 23.00% |
| Operating Income | -56.64% | 404.54% | 273.29% | -13.34% | 157.18% |
| Income Before Tax | -55.15% | 248.52% | 171.10% | -4.42% | 242.95% |
| Income Tax Expenses | 37.11% | -17.99% | 33.18% | -1,418.47% | 36.62% |
| Earnings from Continuing Operations | -56.47% | 229.28% | 161.77% | 57.36% | 250.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.47% | 229.28% | 161.77% | 57.36% | 250.53% |
| EBIT | -56.64% | 404.54% | 273.29% | -13.34% | 157.18% |
| EBITDA | -50.74% | 1,189.30% | 1,033.78% | -11.50% | 117.76% |
| EPS Basic | -57.62% | 225.59% | 160.06% | 52.58% | 239.84% |
| Normalized Basic EPS | -56.32% | 244.32% | 169.13% | -11.63% | 232.66% |
| EPS Diluted | -58.54% | 225.59% | 160.00% | 58.48% | 241.67% |
| Normalized Diluted EPS | -56.70% | 243.02% | 168.62% | -11.39% | 233.63% |
| Average Basic Shares Outstanding | 2.72% | 2.92% | 2.92% | 3.14% | 3.13% |
| Average Diluted Shares Outstanding | 3.57% | 3.84% | 3.56% | 2.85% | 2.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |